Pfizer Inc.PFENYSE
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank79
3Y CAGR-21.9%
5Y CAGR-15.5%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-21.9%/yr
Quarterly compound
5Y CAGR
-15.5%/yr
Recent deceleration
Percentile
P79
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 17.20% |
| Q3 2025 | -6.35% |
| Q2 2025 | 12.50% |
| Q1 2025 | -28.44% |
| Q4 2024 | 30.51% |
| Q3 2024 | -12.20% |
| Q2 2024 | 6.62% |
| Q1 2024 | -22.62% |
| Q4 2023 | 39.17% |
| Q4 2023 | -6.41% |
| Q3 2023 | 2.23% |
| Q2 2023 | -24.17% |
| Q4 2022 | 36.05% |
| Q4 2022 | 11.67% |
| Q3 2022 | 15.68% |
| Q2 2022 | -36.47% |
| Q4 2021 | 44.23% |
| Q4 2021 | -2.76% |
| Q3 2021 | 4.20% |
| Q2 2021 | -26.08% |
| Q4 2020 | 39.97% |
| Q3 2020 | 1.00% |
| Q2 2020 | 2.77% |
| Q1 2020 | -40.06% |
| Q4 2019 | 30.18% |
| Q3 2019 | -7.36% |
| Q2 2019 | 4.96% |
| Q1 2019 | -16.48% |
| Q4 2018 | 14.64% |
| Q3 2018 | -1.39% |
| Q3 2018 | 3.86% |
| Q2 2018 | -25.06% |
| Q4 2017 | 30.25% |
| Q4 2017 | 1.84% |
| Q3 2017 | 3.52% |
| Q2 2017 | -24.99% |
| Q4 2016 | 24.38% |
| Q4 2016 | 1.87% |
| Q3 2016 | 2.54% |
| Q2 2016 | -32.94% |